IMO-8400: Preliminary Phase I/II data

Preliminary data from 17 patients with relapsed or refractory Waldenstrom’s macroglobulinemia in an open-label, dose-escalation, U.S. Phase I/II trial showed that once-weekly 0.6, 1.2 and 2.4 mg/kg IM...